Tag Archives: NYSE:PFE

Cantor Fitzgerald Sticks to Their Buy Rating for Pfizer (PFE)

Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $53. The company’s shares closed on Friday at $42.40. Chen observed: “We reiterate our OW rating and think

The President R&D of Pfizer is Exercising Options

Yesterday it was reported that the President R&D of Pfizer (PFE – Research Report), Mikael Dolsten, exercised options to buy 309,462 PFE shares at $30.75 a share, for a total transaction value of $9.52M. This recent transaction increases Mikael Dolsten’s

Pfizer (PFE) Gets a Buy Rating from Cantor Fitzgerald

In a report released today, Louise Chen from Cantor Fitzgerald reiterated a Buy rating on Pfizer (PFE – Research Report), with a price target of $53. The company’s shares opened today at $44.08. Chen noted: “We reiterate our OW and

Pfizer (PFE) Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on Pfizer (NYSE: PFE) today and set a price target of $53. The company’s shares closed yesterday at $43.93, close to its 52-week high of $45.81. Chen wrote: “. We reiterate

Pfizer (PFE) Gets a Hold Rating from Barclays

Barclays analyst Geoff Meacham maintained a Hold rating on Pfizer (NYSE: PFE) today and set a price target of $40. The company’s shares opened today at $43.68, close to its 52-week high of $44.46. According to TipRanks.com, Meacham is a

Cantor Fitzgerald Believes Pfizer (NYSE: PFE) Still Has Room to Grow

In a report released yesterday, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Pfizer (NYSE: PFE), with a price target of $45. The company’s shares closed yesterday at $42.85, close to its 52-week high of $42.92. Chen said: